Clinical Trials Logo

Hyperemesis Gravidarum clinical trials

View clinical trials related to Hyperemesis Gravidarum.

Filter by:

NCT ID: NCT03056482 Completed - Clinical trials for Cannabis Use Disorder

Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)

HaVOC
Start date: May 21, 2017
Phase: Phase 4
Study type: Interventional

Cannabis Hyperemesis Syndrome (CHS) has become a well-documented syndrome since 2004 and is expected to increase in prevalence with continuing liberalization of marijuana and recognition of the disease. Regardless of whether the association with heavy cannabis use is recognized, there is well-documented resistance to traditional anti-emetic treatment. Given promising reports of the use of intravenous haloperidol, a randomized controlled trial comparing it to the commonly administered anti-emetic ondansetron will contribute to the management of CHS

NCT ID: NCT02989337 Recruiting - Clinical trials for Hyperemesis; Gravidarum, With Dehydration

Endothelial Dysfunction in Hyperemesis Gravidarum

Start date: December 2016
Phase: N/A
Study type: Observational

The purpose of the study is to determine serum inflammatory adhesion molecules levels in hyperemesis gravidarum

NCT ID: NCT02963753 Completed - Clinical trials for Gestational Diabetes

Hyperemesis Gravidarum and 75 Gram Oral Glucose Tolerance Test

Start date: January 2016
Phase: N/A
Study type: Observational

Hyperemesis gravidarum (HEG) is not only nausea and vomiting of pregnancy, but it is also a clinical syndrome including endocrine and metabolic complications. Recently, some investigators have been begun performing researches related to the development of gestational diabetes mellitus (GDM) in pregnant women with HEG because they think about those metabolic and endocrine complications of HEG.In the literature there are few studies assessing how HEG has effects on GDM or 75 gram oral glucose tolerance test (OGTT). So the investigators aim to evaluate the effects of HEG on 75 gram OGTT.

NCT ID: NCT02862496 Recruiting - Clinical trials for Hyperemesis Gravidarum

Bone Health in Hyperemesis Gravidarum

Start date: June 2016
Phase: N/A
Study type: Observational [Patient Registry]

The purpose of the study is to determine whether maternal bone resorption would be seen in Hyperemesis Gravidarum and could be detected in early period using serum vitamin D levels, serum calcium (Ca) levels, serum parathormone (PTH) levels and urine N- telopeptide levels in the patients with Hyperemesis Gravidarum.

NCT ID: NCT02830321 Completed - Clinical trials for Hyperemesis Gravidarum

The Association of Helicobacter Pylori in the Pathogenesis of Hyperemesis Gravidarum in Pregnant Women

AOHPIPOHGIPW
Start date: March 2015
Phase: N/A
Study type: Observational

The purpose of this study to explore the association between Hyperemesis Gravidarum in pregnant women and Helicobacter pylori infection.

NCT ID: NCT02619188 Recruiting - Pregnancy Clinical Trials

Nutritional Markers in Normal and Hyperemesis Pregnancies

PUQE-M
Start date: September 2015
Phase: N/A
Study type: Observational

This study evaluate the rate of nausea and nutritional status in patients with hyperemesis gravidarum (severe nausea and vomiting in pregnancy) and healthy pregnant women using a questionnaire (PUQE-score), self-reported food/drink intake form and blood test. The Investigators aim for developing normal range of prealbumin measurements (reference values) during first trimester of pregnancy.

NCT ID: NCT02541682 Completed - Clinical trials for Hyperemesis Gravidarum

Assessment of the Relationship Between Affective Temperament and the Severity of Nausea and Vomiting in Early Pregnancy

Start date: March 2013
Phase: N/A
Study type: Interventional

In this study, the investigators aimed to research the relationship between affective temperament with the severity of the symptoms of nausea and vomiting in early pregnancy. The investigators aimed to assess temperament differences between healthy pregnant women and pregnant women suffering from mild, moderate, and severe hyperemesis gravidarum.

NCT ID: NCT02300155 Completed - Pregnancy Clinical Trials

Improving Multivitamin Supplementation to Pregnant Women

Start date: October 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the tolerability of Pregvit® to a common prenatal vitamin (Orifer® F) among pregnant women with morning sickness or those suffering from a variety of conditions.

NCT ID: NCT02163434 Completed - Clinical trials for Hyperemesis Gravidarum

Comparison of Gabapentin and Metoclopramide for Treating Hyperemesis Gravidarum

Start date: June 2014
Phase: Phase 2
Study type: Interventional

The investigators will compare the effectiveness of gabapentin to metoclopramide for 1 week among 60 women with hyperemesis gravidarum (HG) in this randomized, double-blinded trial. After completion of the 1-week double-blind phase, subjects will be offered open-label gabapentin with rescue metoclopramide until their symptoms no longer require treatment. Enrollment will occur at the University's at Buffalo, of Rochester and of Wisconsin.

NCT ID: NCT01836835 Completed - Clinical trials for Hyperemesis Gravidarum

Pregnancy Specific Nausea Questionnaire (PUQE) Translated and Tested in Norwegian

PUQE-N
Start date: May 2013
Phase: N/A
Study type: Observational [Patient Registry]

Nausea in early pregnancy (emesis gravidarum) is very common but most often self-limiting. Hyperemesis gravidarum; where nausea and vomiting is severe and protracted is potentially dangerous for the woman and her foetus and necessitates hospital treatment. An English questionnaire (PUQE; Pregnancy Unique Questionnaire of Emesis) exists that can differentiate between uncomplicated emesis and the severe hyperemesis condition. This questionnaire has been translated to Norwegian. The investigators want to test the ability of this questionnaire to differentiate the grade of nausea/vomiting between a group of presumed normal pregnant woman and patients treated for hyperemesis gravidarum in a Norwegian population. The investigators also want to relate the PUQE questionnaire scoring to the women/patients' self-reported nutritional intake during 24 hours.